Most noninferiority trials were not designed to preserve active comparator treatment effects.


Journal

Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383

Informations de publication

Date de publication:
06 2019
Historique:
received: 04 07 2018
revised: 30 01 2019
accepted: 01 03 2019
pubmed: 13 3 2019
medline: 19 5 2020
entrez: 13 3 2019
Statut: ppublish

Résumé

To evaluate whether noninferiority trials are designed to adequately preserve the historical treatment effect of their active comparators. We reviewed 162 noninferiority trials published in high-impact medical journals. We assessed whether trials were designed to ensure that interventions could only be declared noninferior if they preserved at least 50% of the active comparator's historical treatment effect. Only 25 of 162 trials (15%) were designed so that interventions could only be declared noninferior if they preserved at least 50% of the active comparator's historical treatment effect. Most trials did not provide evidence that the active comparator was effective (n = 101), provided inadequate evidence (n = 18), or used a noninferiority margin that was too wide (n = 18). In a subset of 61 noninferiority trials which referenced a prior randomized trial or meta-analysis evaluating the active comparator, only 25 (41%) used a noninferiority margin small enough to preserve at least 50% of the active comparator's treatment effect. Overall, 14 of 162 noninferiority trials (9%) would have allowed the intervention to be declared noninferior even if it was worse than either placebo or another historical control. Most noninferiority trials published in major medical journals could allow erroneous declarations of noninferiority.

Identifiants

pubmed: 30858020
pii: S0895-4356(18)30599-7
doi: 10.1016/j.jclinepi.2019.03.003
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

82-89

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Michael Tsui (M)

Schulich School of Medicine and Dentistry, 1151 Richmond St, London, Ontario N6A 5C1, Canada.

Sunita Rehal (S)

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, 90 High Holborn, London WC1V 6LJ, UK.

Vipul Jairath (V)

Department of Medicine, University of Western Ontario, 1151 Richmond St, London, Ontario N6A 5C1, Canada; Department of Epidemiology and Biostatistics, University of Western Ontario, 1151 Richmond St, London, Ontario N6A 5C1, Canada.

Brennan C Kahan (BC)

Pragmatic Clinical Trials Unit, Queen Mary University of London, London, E1 2AB UK. Electronic address: b.kahan@qmul.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH